BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling

Gut

Volumn 65, Issue 7, 2016, Pages 1151-1164

  Urban, Bettina C ^a   Collard, Tracey J ^a   Eagle, Catherine J ^a   Southern, Samantha L ^a   Greenhough, Alexander ^a   Hamdollah Zadeh, Maryam ^a   Ghosh, Anil ^b   Poulsom, Richard ^b   Paraskeva, Christos ^a   Silver, Andrew ^b   Williams, Ann C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; HOMODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESALAZINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 3; PROTEIN KINASE B; PROTEIN P50; PROTEIN P52; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTO-ONCOGENE PROTEIN BCL-3; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCL 3 GENE; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLON CARCINOGENESIS; COLORECTAL CANCER CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; HCA7 CELL LINE; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SW480 CELL LINE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; COLON; COLORECTAL TUMOR; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; RECTUM; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLON; COLORECTAL NEOPLASMS; HCT116 CELLS; HUMANS; MESALAMINE; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECTUM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR BURDEN;

EID: 84931439033     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308270     Document Type: Article

References (56)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Colorectal Cancer [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan. iarc.fr/Pages/fact-sheets-cancer.aspx (accessed 07/08/2014).
2. Cancer Research UK. Bowel cancer incidence report [Internet]. Cancer Research UK, 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/ incidence/uk-bowel-cancer-incidence-statistics#geog (accessed 07/08/2014).
3. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-17.
4. Petherick KJ, Williams AC, Lane JD, et al. Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J 2013;32:1903-16.
5. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
6. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
7. Harmey JH, Bucana CD, Lu W, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002;101:415-22.
8. Nishikori M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol 2005;45:15-24.
9. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-6.
10. Garg A, Aggarwal BB. Nuclear transcription factor-B as a target for cancer drug development. BMC Cancer 2002;16:1053-68.
11. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004;14:64-9.
12. Roy HK, Olusola BF, Clemens DL, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-5.
13. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990;60:991-7.
14. Au WY, Horsman DE, Ohno H, et al. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma 2002;43:813-16.
15. Canoz O, Rassidakis GZ, Admirand JH, et al. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol 2004;17:911-17.
16. Schlette E, Rassidakis GZ, Canoz O, et al. Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19. Am J Clin Pathol 2005;123:465-71.
17. Maldonado V, Melendez-Zajgla J. Role of Bcl-3 in solid tumors. Mol Cancer 2011;10:152.
18. Cogswell PC, Guttridge DC, Funkhouser WK, et al. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000;19:1123-31.
19. Choi HJ, Lee JM, Kim H, et al. Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun 2010;400:396-402.
20. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003;63:8293-301.
21. Pallares J, Martínez-Guitarte JL, Dolcet X, et al. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 2004;204:569-77.
22. Puvvada SD, Funkhouser WK, Greene K, et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010;78:181-8.
23. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-224.
24. Kashatus D, Cogswell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006;20:225-35.
25. Nolan GP, Fujita T, Bhatia K, et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 1993;13: 3557-66.
26. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-39.
27. Franzoso G, Bours V, Park S, et al. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 1992;359: 339-42.
28. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
29. Caamaño JH, Perez P, Lira SA, et al. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol 1996;16:1342-8.
30. Wessells J, Baer M, Young HA, et al. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 2004;279:49995-50003.
31. Liu Z, Jiang Y, Hou Y, et al. The lκB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol 2013;5:280-2.
32. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8: 976-90.
33. Wilkins JA, Sansom OJ. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 2008;68:4963-6.
34. Collins PE, Kiely PA, Carmody RJ. Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor κB (NF-κB) p50. J Biol Chem 2014;289:7059-67.
35. Brocke-Heidrich K, Ge B, Cvijic H, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006;25:7297-304.
36. Skeen VR, Collard TJ, Southern SL, et al. BAG-1 suppresses expression of the key regulatory cytokine transforming growth factor β (TGF-β1) in colorectal tumour cells. Oncogene 2013;32:4490-9.
37. Paraskeva C, Finerty S, Mountford RA, et al. Specific cytogenetic abnormalities in two new human colorectal adenoma-derived epithelial cell lines. Cancer Res 1989;49:1282-6.
38. Williams AC, Browne SJ, Yeudal WA, et al. Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma. Oncogene 1993;8:3063-72.
39. Hague A, Manning AM, Hanlon KA, et al. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55:498-505.
40. Keutgens A, Shostak K, Close P, et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol 2010;30:4006-21.
41. Viatour P, Dejardin E, Warnier M, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 2004;16:35-45.
42. Barnes JD, Arhel NJ, Lee SS, et al. Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis 2005;10:301-11.
43. Williams C, Panaccione R, Ghosh S, et al. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:237-48.
44. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201:1205-15.
45. Stolfi C, Pallone F, Monteleone G. Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol 2012;2012:980458.
46. Greenhough A, Patsos HA, Williams AC, et al. The cannabinoid delta (9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 2007;121:2172-80.
47. Southern SL, Collard TJ, Urban BC, et al. BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis. Oncogene 2012;31:2761-72.
48. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.
49. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:1346-50.
50. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
51. Nassif NT, Lobo GP, Wu X, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004;23:617-28.
52. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000;9:283-7.
53. Blanco-Aparicio C, Renner O, Leal JF, et al. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86.
54. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16:34-44.
55. Ozes ON, Mayo LD, Gustin JA, et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
56. Agarwal A, Das K, Lerner N, et al. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005;24:1021-31.